Our Mission

We are a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Our robust pipeline includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE), as well as wet age-related macular degeneration (wAMD).

Leveraging our next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. We are well positioned with core capabilities, which include clinical development and in-house manufacturing expertise, specifically in process development and assay development.

Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients with rare and ocular diseases.

Core Values

At Adverum, our values underscore our business and shape how we think of the patients we hope to help, how we apply science to medicine, and how we work and grow as a company.

INTEGRITY We are honest with our purpose, courageous against the unknown, and genuine through communications. RESPECT, TRANSPARENCY, HONESTY
COMMUNITY We collaborate as a team to solve difficult problems, and support one another in these endeavors. COLLABORATE TO BREAK BARRIERS
EMPOWERMENT We bring our best selves to take ownership, be accountable, learn, grow, and achieve success. FREEDOM TO FULFILL INDIVIDUAL POSSIBILITIES
PATIENT FOCUSED We are humbled and inspired by our patients, with sincere empathy as we strive to understand their individual journeys. PUT THE PATIENT FIRST
PIONEERING We are not afraid to create new paths forward, leveraging our passion, grit, and resilience in doing so. EXPLORE TO CREATE POSSIBILITY

Our Leadership Team

Print All
Leone Patterson Interim President and Chief Executive Officer, Chief Financial Officer
Mehdi Gasmi, Ph.D. Chief Science and Technology Officer
Linda Neuman, M.D. Interim Chief Medical Officer
Jennifer Cheng, Ph.D., J.D. Vice President and General Counsel
Paul B. Cleveland Chairman
Eric G. Carter, M.D., Ph.D. Director
Mitchell Finer, Ph.D. Co-Founder
Patrick Machado, J.D. Director
Richard N. Spivey, Pharm.D., Ph.D. Director
Thomas F. Woiwode, Ph.D. Director

Contact Us

Adverum Biotechnologies
1035 O’Brien Drive
Menlo Park, CA 94025
Tel: 650-656-9323
Fax: 650-362-1908
General Inquiry: info@adverum.com

  • *Indicates required field